Tandem Diabetes CEO vests 15,916 RSUs, withholds tax
For TANDEM DIABETES CARE INC (TNDM), President & CEO John F. Sheridan reported the vesting and settlement of restricted stock units on August 15, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
For TANDEM DIABETES CARE INC (TNDM), President & CEO John F. Sheridan reported the vesting and settlement of restricted stock units on August 15, 2026. Two RSU grants covering 5,982 and 9,934 units, awarded under the company’s 2023 Long-Term Incentive Plan, were converted into an equal number of common shares at no exercise price. To cover associated tax withholding on these vestings, the issuer withheld 3,044 and 5,055 common shares at a reference value of $22.72 per share; according to the disclosure, these were not open-market sales but shares retained by the company for tax purposes.
Insider Trade Summary
15,916 shares exercised/converted
Exercise
6 txns
Insider
Sheridan John F
Role
PRESIDENT & CEO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Unit F2, F3, F4 | 5,982 | $0.00 | $0.00 |
| Exercise | Restricted Stock Unit F5, F3, F6 | 9,934 | $0.00 | $0.00 |
| Exercise | Common Stock | 5,982 | $0.00 | $0.00 |
| Tax Withholding | Common Stock F1 | 3,044 | $22.72 | $69K |
| Exercise | Common Stock | 9,934 | $0.00 | $0.00 |
| Tax Withholding | Common Stock F1 | 5,055 | $22.72 | $115K |
Holdings After Transaction:
Restricted Stock Unit — 87,484 contracts (Direct);
Common Stock — 160,260 shares (Direct)
Footnotes (6)
- F1. Shares withheld by the Issuer to satisfy tax withholding requirements upon the vesting of restricted stock units (RSUs). No shares were sold.
- F2. Awarded on May 23, 2024 pursuant to the Tandem Diabetes Care Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan).
- F3. Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan.
- F4. One-third of the RSUs granted on May 23, 2024 vested on May 15, 2025, with the remaining RSUs vesting in eight (8) equal quarterly installments thereafter, subject to the terms of the 2023 Plan.
- F5. Awarded on May 30, 2025 pursuant to the 2023 Plan.
- F6. One-third of the RSUs granted on May 30, 2025 vested on May 15, 2026, with the remaining RSUs vesting in eight (8) equal quarterly installments thereafter, subject to the terms of the 2023 Plan.
Key Figures
RSUs vested (grant 1): 5,982 units
RSUs vested (grant 2): 9,934 units
Total derivative shares exercised: 15,916 shares
+4 more
7 metrics
RSUs vested (grant 1)
5,982 units
Restricted Stock Units converted into common stock on August 15, 2026
RSUs vested (grant 2)
9,934 units
Restricted Stock Units converted into common stock on August 15, 2026
Total derivative shares exercised
15,916 shares
Aggregate RSU exercises (code M) reported in transaction summary
Shares withheld for taxes (lot 1)
3,044 shares
Common shares withheld to satisfy tax withholding requirements
Shares withheld for taxes (lot 2)
5,055 shares
Additional common shares withheld to satisfy tax withholding requirements
Per-share tax valuation
$22.72 per share
Reference value for common shares withheld under code F transactions
Total shares used for tax withholding
8,099 shares
Exercise price or tax liability shares in transaction summary
Key Terms
Restricted Stock Unit, RSUs, tax withholding requirements, Long-Term Incentive Plan, +1 more
5 terms
Restricted Stock Unit financial
"security_title: "Restricted Stock Unit""
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
RSUs financial
"vested on May 15, 2025, with the remaining RSUs vesting"
RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.
tax withholding requirements financial
"Shares withheld by the Issuer to satisfy tax withholding requirements"
Long-Term Incentive Plan financial
"pursuant to the Tandem Diabetes Care Inc. 2023 Long-Term Incentive Plan"
A long-term incentive plan is a company program that pays executives or employees with stock, options, or cash tied to multi-year performance goals, where the rewards become theirs only after meeting conditions over time. Think of it as a delayed bonus or retirement-style reward that aligns employees’ interests with shareholders by encouraging them to boost long-term value; investors watch these plans because they affect pay costs, share dilution and management incentives.
contingent right financial
"Each RSU represents a contingent right to receive either one share"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did TNDM CEO John F. Sheridan report in this Form 4?
John F. Sheridan reported RSU vesting and settlement into common stock on August 15, 2026. The transactions reflect equity compensation mechanics and related tax withholding, rather than open-market purchases or sales.
How many Tandem Diabetes Care (TNDM) RSUs vested for the CEO on August 15, 2026?
Two RSU tranches of 5,982 and 9,934 units vested and were settled into common stock. These RSUs were granted under Tandem Diabetes Care’s 2023 Long-Term Incentive Plan on May 23, 2024 and May 30, 2025.
Does this TNDM Form 4 indicate a 10b5-1 trading plan for the CEO’s transactions?
The Form 4 indicates the Rule 10b5-1 checkbox is not marked, and the footnotes do not describe a trading plan. The reported activity relates to equity award vesting and tax withholding, not a pre-arranged trading program.
Which Tandem Diabetes Care equity plan governed the RSUs in this Form 4?
The RSUs were granted under the Tandem Diabetes Care Inc. 2023 Long-Term Incentive Plan. Footnotes state each RSU represents a contingent right to one common share or cash, per the plan’s terms and related award agreements.
AI-generated analysis. How Rhea-AI works. Not financial advice.
